{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:12:48Z","timestamp":1777299168884,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,31]]},"DOI":"10.7759\/cureus.91338","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T14:59:25Z","timestamp":1756652365000},"source":"Crossref","is-referenced-by-count":2,"title":["Adrenal Insufficiency Induced by Checkpoint Inhibitor Therapy in a Patient With Metastatic Acral Melanoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Faith Oluwaseun","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Katsaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianne","family":"Garcet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uthra","family":"Rajendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth","family":"Akunuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma P","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015, 348:56-61. 10.1126\/science.aaa8172","journal-title":"Science"},{"key":"ref2","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"389","author":"Wolchok JD","year":"2023","unstructured":"Wolchok JD, Kluger HM, Callahan MK, et al.. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2023, 389:1231-1242.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-580. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref4","article-title":"Endocrine toxicity of immune-checkpoint inhibitors","volume":"37","author":"Johnson DB","year":"2019","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Endocrine toxicity of immune-checkpoint inhibitors. J Clin Oncol. 2019, 37:2721-2732.","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright JJ","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021, 17:389-99. 10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun DJ","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017, 13:195-207. 10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai Y","year":"2019","unstructured":"Zhai Y, Ye X, Hu F, et al.. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J Immunother Cancer. 2019, 7:286. 10.1186\/s40425-019-0754-2","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00462-8","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"399","author":"Tawbi HA","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al.. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. Lancet. 2022, 399:1799-1809. 10.1016\/S0140-6736(22)00462-8","journal-title":"Lancet"},{"key":"ref9","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"4","author":"Postow MA","year":"2018","unstructured":"Postow MA, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. JAMA Oncol. 2018, 4:95-96.","journal-title":"JAMA Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000357","article-title":"Endocrine dysfunction following immune checkpoint inhibitor therapy","volume":"24","author":"Konda B","year":"2017","unstructured":"Konda B, Nabhan F, Shah MH. Endocrine dysfunction following immune checkpoint inhibitor therapy. Curr Opin Endocrinol Diabetes Obes. 2017, 24:337-47. 10.1097\/MED.0000000000000357","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0018","article-title":"The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope","volume":"147","author":"Husebye ES","year":"2006","unstructured":"Husebye ES, Bratland E, Bredholt G, et al.. The substrate-binding domain of 21-hydroxylase, the main autoantigen in autoimmune Addison's disease, is an immunodominant T cell epitope. Endocrinology. 2006, 147:2411-6. 10.1210\/en.2006-0018","journal-title":"Endocrinology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje AT","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, et al.. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014, 99:4078-85. 10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al.. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll DM","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012, 12:252-64. 10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco LM","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010, 236:219-42. 10.1111\/j.1600-065X.2010.00923.x","journal-title":"Immunol Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian SL","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al.. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012, 366:2443-54. 10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen L","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015, 125:3384-91. 10.1172\/JCI80011","journal-title":"J Clin Invest"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama S","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, et al.. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014, 6:230ra45. 10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez E","year":"2016","unstructured":"Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016, 21:804-816.","journal-title":"Oncologist"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello SM","year":"2013","unstructured":"Corsello SM, Barnabei A, Marchetti P, et al.. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013, 98:1361-75. 10.1210\/jc.2012-4075","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101787","article-title":"Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced adrenal insufficiency","volume":"38","author":"Xiang J","year":"2023","unstructured":"Xiang J, Liu X, Hao Y, et al.. Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced adrenal insufficiency. Transl Oncol. 2023, 38:101787. 10.1016\/j.tranon.2023.101787","journal-title":"Transl Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91032-6","article-title":"Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency","volume":"11","author":"Manaka K","year":"2021","unstructured":"Manaka K, Sato J, Takeuchi M, et al.. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency. Sci Rep. 2021, 11:11617. 10.1038\/s41598-021-91032-6","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham CE","year":"2018","unstructured":"Higham CE, Olsson-Brown A, Carroll P, et al.. Society for endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018, 7:G1-7. 10.1530\/EC-18-0068","journal-title":"Endocr Connect"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00027","article-title":"Adequacy of immune checkpoint inhibitor-associated thyroid function monitoring after therapy","author":"Velez MA","year":"2025","unstructured":"Velez MA, Kang ES, Thompson CA, et al.. Adequacy of immune checkpoint inhibitor-associated thyroid function monitoring after therapy. JCO Oncol Pract. 2025, OP2500027. 10.1200\/OP-25-00027","journal-title":"JCO Oncol Pract"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews LP","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017, 276:80-96. 10.1111\/imr.12519","journal-title":"Immunol Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi T","year":"2020","unstructured":"Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020, 8:10.1136\/jitc-2020-001014","journal-title":"J Immunother Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/BF00241263","article-title":"Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand","volume":"39","author":"Huard B","year":"1994","unstructured":"Huard B, Gaulard P, Faure F, et al.. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics. 1994, 39:213-7. 10.1007\/BF00241263","journal-title":"Immunogenetics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso JF","year":"2007","unstructured":"Grosso JF, Kelleher CC, Harris TJ, et al.. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007, 117:3383-92. 10.1172\/JCI31184","journal-title":"J Clin Invest"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi HA","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, et al.. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022, 386:24-34. 10.1056\/NEJMoa2109970","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier P","year":"2017","unstructured":"Cukier P, Santini FC, Scaranti M, Hoff AO. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer. 2017, 24:T331-47. 10.1530\/ERC-17-0358","journal-title":"Endocr Relat Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher K","year":"2024","unstructured":"Fletcher K, Johnson DB. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer. 2024, 12:10.1136\/jitc-2023-008591","journal-title":"J Immunother Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona Z","year":"2023","unstructured":"Cardona Z, Sosman JA, Chandra S, Huang W. Endocrine side effects of immune checkpoint inhibitors. Front Endocrinol (Lausanne). 2023, 14:1157805. 10.3389\/fendo.2023.1157805","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley R","year":"2021","unstructured":"Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021, 21:e212-22. 10.7861\/clinmed.2020-0827","journal-title":"Clin Med (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/381402-adrenal-insufficiency-induced-by-checkpoint-inhibitor-therapy-in-a-patient-with-metastatic-acral-melanoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T14:59:26Z","timestamp":1756652366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/381402-adrenal-insufficiency-induced-by-checkpoint-inhibitor-therapy-in-a-patient-with-metastatic-acral-melanoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.91338","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,31]]}}}